Supreme Pharmacist System Chapter 307: Ready to go

At 10 am on June 6, 2022, Universal Bio held a grand press conference at Jiangzhou International Conference Center.

In the past year or so, Universal Bio has held a press conference every three or five years, and each time is a major breakthrough in medicine or a technological innovation.

Because of this, as soon as the news was released, countless reporters from home and abroad flocked there, and thousands of reporters filled the huge press room.

Lin Wei, vice president and chief press officer of Universal Bio, presided over the press conference.

Under the attention of countless reporters, Lin Wei said with excitement: "Good morning, all guests and reporters, friends, welcome to the press conference of the world..."

Kaka Kaka! ! !

Just as Lin Wei was speaking, the press room instantly became a sea of ​​spotlights.

Lin Wei paused and said, "I want to tell you a piece of good news here. Zhou Wen, Chief Scientist of Universal Bio, Lin Ming, Senior Engineer, and He Junfeng, Deputy Director and Chief Scientist of the Institute of Hepatitis B of the Chinese Academy of Sciences. Under the leadership of and with the continuous efforts of hundreds of other researchers, we have successfully conquered hepatitis B virus!"

The press conference was quiet at first, but the next second, there was a huge humming sound.

"What do you mean, is a new drug developed?"

"I still don't understand, conquering is healing!"

"Impossible, isn't the hepatitis B virus incurable?"

"Then I don't know..."

Lin Wei gave the reporters more than ten seconds to digest what he just said, and then explained their research results.

When reporters at the scene learned that this drug will cure nearly 300 million hepatitis B virus patients worldwide, heated discussions erupted.

…

The news that the hepatitis B virus was conquered instantly spread all over the world.

Countless hepatitis B patients were naturally very excited when they saw the news.

However, some more than a dozen pharmaceutical companies that were researching new hepatitis B drugs and even reached the clinical trial stage were struck by lightning when they heard the news.

Especially the 6 pharmaceutical companies that have obtained the data of Universal Bio's formula, they spent so much energy to do this, but in the end they all did it in vain.

…

In the inner ring of Kyoto, inside a building with the national emblem hanging.

A man with a face with a Chinese character was reading an internal reference news, and he read the news very quickly.

With a slightly surprised look on his face, he asked in a deep voice, "Is this news real?"

The confidential secretary who was sorting out the information immediately said respectfully: "Yes, Chief, the experts at the Food and Drug Administration have tested it with DGD technology, and it is absolutely true."

The man with the face of the Chinese character nodded, a smile appeared on his serious face, and said with a smile: "No wonder you dare to make a deal with me, it seems that you are already prepared!"

The confidential secretary smiled and said, "Yes! Professor Zhou's level in the field of medicine is indeed worthy of being a genius doctor."

It is self-evident how important DGD technology is to pharmaceutical companies. It can be regarded as one of the greatest inventions in the pharmaceutical industry. Such high-precision technology is not something that Universal Bio can make public if it wants to be made public. Consent at the national level.

The same is true for European and American countries. The technology of European and American companies is not easily exported to China.

So it is conceivable that when Universal Bio proposed the sharing of DGD technology, how fiercely opposed it was?

Including many high-level bosses who trust Zhou Wen very much, they also hold objections.

However, Zhou Wen still persuaded a group of bigwigs.

Zhou Wen's reasons are very good. DGD technology is important, but to regain the standard of the global pharmaceutical market, relying on one DGD technology is far from enough.

First of all, NMPA has always followed the FDA's lead, and freezing three feet is not a day's cold. It will not take a day or two to completely reverse this situation.

Because there are many interests involved.

If there is interest, there will be disputes. Many people are reluctant to leave their comfort zone and explore unknown areas. If you do well, you will be the leader. Therefore, the promotion of DGD technology in China has encountered great resistance.

The second and most important point is that European and American countries will definitely not allow DGD technology whose core technology is mastered by Chinese companies to be implemented in their own countries. Even if the academic community supports it, it is useless for pharmaceutical companies to advocate.

Don't even think about it.

Then there is the problem. Even if China's NMPA adopts the DGD technical standard, if the drugs developed by Universal Bio are to be sold abroad, they still need to go through the time-consuming and lengthy clinical trial procedures again.

Some people may want to say that it is their business that European and American countries are willing to stand still, and the big deal is to sell them in China.

But Zhou Wen can't wait. His new drug development speed is far beyond the imagination of ordinary people. He has a large number of new drugs to be brought to the market. Cream, wrinkle cream as fast as the market.

The DGD technology is the stepping stone to the European and American pharmaceutical market.

With the speed of Zhou Wen's drug research and development, European and American pharmaceutical companies together are not enough for him.

Therefore, the sharing of DGD technology with Europe and the United States is not for the convenience of European and American countries, but for himself.

Of course, these ordinary people cannot know.

The reason why the upper-level leaders agreed to Zhou Wen was only because of his medical skills.

Zhou Wen's medical skills have almost reached the level of perfection, and the master of Chinese medicine is no longer enough to describe him. The bosses and family members above are now calling him "magic doctor".

Can you imagine the weight of his words?

Therefore, when he patted his chest and assured the chiefs that he would earn back the DGD technology, the chiefs finally agreed with his suggestion.

Now it seems that Zhou Wen has already prepared the killer!

…

…

Half a month later ~IndoMTL.com~Universe Biotech's "Qingganling Preparation" codenamed PD0079, as well as the second-class new drugs from four or five other pharmaceutical companies, became the first batch of DGD technology experimental objects in China. A phase one clinical trial was conducted.

It usually takes 3 to 6 months for a phase I clinical trial. After using the DGD technology, it only took one week to complete the trial.

Of course, "Qingganling Preparation" successfully passed the first phase of clinical trials without any accident.

Once the news came out, it caused a huge sensation.

Countless medical laboratories and pharmaceutical companies are surprised and envious of the efficiency and speed of DGD technology.

Relevant departments in Europe, America, Japan and South Korea have also accelerated the approval of DGD technology.

Soon, Han Kingdom became the second country to adopt DGD technology.

Japanese benzene followed.

Then Germany, Portugal, France, Italy, Russia...

At this speed like a competition, "Qingganling Preparation" has passed the second phase of clinical trials.

Everything is ready to go...

https://

Genius remembers the address of this site in one second: . Mobile version reading URL: